Last updated: February 22, 2026
What is NDC 00409-3412?
NDC 00409-3412 corresponds to Liposomal doxorubicin (brand name: Doxil or Caelyx), a chemotherapeutic agent used primarily for ovarian cancer, multiple myeloma, and AIDS-related Kaposi's sarcoma. The drug is administered intravenously and is a liposomal formulation of doxorubicin, designed to improve drug targeting and reduce toxicity.
Market Size and Key Players
Current Market Landscape
| Aspect |
Data |
| Global oncology drug market |
Estimated at USD 210 billion in 2022, expected to grow at 7.9% CAGR through 2028 [1]. |
| Doxil/Caelyx market share |
Dominant within liposomal chemotherapies; approximately 45% of the liposomal drug market in oncology as of 2022 [2]. |
| Leading manufacturers |
Janssen Biotech (Johnson & Johnson), Teva Pharmaceuticals. |
| Authorized indications |
Ovarian cancer, multiple myeloma, Kaposi's sarcoma. |
Competition
| Competitors |
Marketed Alternatives |
Price Range (per vial, USD) |
Notes |
| Generic doxorubicin |
$10–$50 per vial; limited liposomal formulations |
Lower cost, less effective in targeting |
Less effective in specific indications |
| Liposomal formulations (non-Doxil) |
AmBisome, others; primarily antifungals |
$1,200–$1,900 per vial |
Different indications; similar technology platform |
Regulatory Status
- Marketed as Doxil in the U.S.
- Abbreviated New Drug Applications (ANDAs) for generics approved in multiple countries.
- Patent expiration for Doxil in major markets occurred around 2013–2015, opening opportunities for generics.
Price Trends and Projections
Historical Pricing Trends (U.S. Market)
- 2010–2015: Doxil priced at approximately USD 2,500–3,500 per vial depending on dosage.
- Post-2015: Entry of generics led to price reduction; current average around USD 2,000–2,500 per vial.
- Recent years (2020–2022): Slight price increases in the absence of direct generics competition, driven by inflation and supply chain factors.
Future Price Projections (2023–2028)
| Year |
Estimated Price Range (per vial, USD) |
Key Influencing Factors |
| 2023 |
$2,200–$2,700 |
Potential new biosimilar entrants, supply chain stabilization, inflation. |
| 2024 |
$2,200–$2,800 |
Patent disputes, pricing power of brand if exclusivity is restored. |
| 2025 |
$2,100–$2,600 |
Emergence of biosimilars and generics, downward pressure. |
| 2026 |
$2,000–$2,500 |
Increased generic market penetration, cost containment in healthcare. |
| 2027 |
$1,900–$2,400 |
Biological licensing, price negotiations. |
| 2028 |
$1,800–$2,300 |
Greater biosimilar adoption, market competition. |
Factors Impacting Pricing
- Biosimilar approval: Several biosimilars in late-stage development may enter the market by 2025, exerting price pressure.
- Regulatory landscape: Policy changes favoring biosimilar adoption could lower prices.
- Manufacturing costs: Liposomal formulations are complex; manufacturing advances could stabilize prices.
- Market demand: Growing indications and expanded use could sustain higher prices temporarily.
Regulatory and Commercial Opportunities
- Market expansion in emerging markets with increasing cancer prevalence.
- Development of biosimilars could significantly reduce costs and increase accessibility.
- Combination therapies using liposomal doxorubicin with immune checkpoint inhibitors are under investigation, potentially expanding indications.
Risks and Challenges
- Delay or failure of biosimilar approval.
- Patent litigation extending exclusivity.
- Reimbursement issues influenced by healthcare policy changes.
- Competition from newer targeted therapies and immunotherapies.
Key Takeaways
- NDC 00409-3412 (Doxil/Caelyx) is a mature oncology product with established efficacy.
- The global market faces pressure from biosimilars, leading to a decline in prices in coming years.
- Current prices hover around USD 2,200–2,500 per vial in the U.S.
- Market growth depends on biosimilar penetration, regulatory policies, and emerging therapeutic combinations.
- Long-term pricing will likely trend downward, approaching USD 1,800–2,300 per vial by 2028.
5 FAQs
What are the main competitors to NDC 00409-3412?
Generic doxorubicin formulations and biosimilar liposomal doxorubicin products.
When are biosimilars expected to impact prices significantly?
Likely between 2024 and 2026, depending on regulatory approvals and market acceptance.
What factors could sustain higher prices?
Lack of biosimilar competition, patent protection conflicts, and high manufacturing costs.
How does market demand influence future prices?
Increased indications and use expand volume, which can offset lower per-unit prices. However, bios.Menu. less likely to compensate for significant price declines.
What is the outlook for healthcare affordability?
Prices are expected to decline, but liposomal formulations will still command premium prices compared to non-liposomal therapies.
References
[1] Market Research Future. (2022). Global oncology drug market report.
[2] Grand View Research. (2022). Liposomal drug delivery systems market analysis.
[3] U.S. Food and Drug Administration. (2023). Approved biosimilars and patent status.
[4] IQVIA. (2022). Oncology drug pricing and reimbursement trends.
[5] EvaluatePharma. (2022). Oncology pipeline and market forecast.
